Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery

Next Previous
Trial Profile

Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Peripheral arterial disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Cook Medical

    • Most Recent Events

    • 13 Nov 2023 Results of sub-analysis assessing the association of patients" pre-procedural health status measured by EQ-5D-3L Index (EQ-5D), a validated PROs instrument and the 12-month treatment durability outcomes measured as primary patency and target lesion revascularization, presented at the American Heart Association Scientific Sessions 2023.
    • 10 Sep 2019 According to Cook Medical media release, data presented by Dr. Dake have been published online in CardioVascular and Interventional Radiology (CVIR).
    • 10 Sep 2019 According to Cook Medical media release, Dr. Dake presented new 5-year data from this study performed to obtain FDA approval at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conference.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top